CRP and diabetes mellitus: A systematic review and meta-analysis from 2021 showed lowered c-reactive protein (CRP) and tumor ​necrosis ​factor alpha (TNF-α) levels in participants receiving a GLP-1RA compared to participants receiving either standard diabetes treatments or placebo, which suggests certain anti-inflammatory properties of GLP-1RAs [21].